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Over the past ﬁve decades ovarian cancer has been of
considerable interest to clinical cancer investigators due to
the fact that it is among the most chemosensitive of all
solid tumors [1]. Unfortunately, despite the advances in
the chemotherapeutic management of this malignancy, the
large majority of patients ultimately recur, progress, and
ultimatelydieasadirectresultofcomplicationsofthedisease
process.Thus, thereis acritical need to ﬁndnovel agentsthat
may favorably impact the natural history of ovarian cancer.
In recent years there has been a particular focus in the
cancer research community to discover and subsequently
develop clinically active drugs that are capable of speciﬁcally
targeting biological pathways relevant in a particular tumor
type (e.g., ovarian cancer) and even within a speciﬁc patient
withthattypeofcancer(so-called,“personalizedmedicine”).
Research in this arena in ovarian cancer remains in its early
stages although a number of quite exciting developments
have recently been reported in the peer-reviewed medical
literature that suggest the realistic potential that this novel
general class of drugs will soon become important com-
ponents of “standard-of-care” in the management of this
diﬃcult malignancy.
In this special issue, investigators from around the
world have contributed to this literature by summarizing a
number of important developments. In the papers of this
special issue, an initial discussion of the role of surgical
cytoreduction in the malignancy is followed by an overview
of the management of recurrent ovarian cancer and the
relevance of molecular abnormalities in speciﬁc ovarian
cancer subtypes.
This is followed by several excellent and comprehensive
overviews of the possible roles of targeted therapy in
ovarian cancer, the potential impact of antiangiogenic drugs,
epidermal growth factor and PARP inhibitors, disruption of
insulin and glucose pathways, and novel treatments aﬀecting
histone deacetylase and metastatic colonization, as well as an
innovative approach to immunotherapy in the malignancy.
The peer-reviewed papers in this special issue provide
important insight into both the current and future manage-
ment of epithelial ovarian cancer.
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